|Bid||77.38 x 800|
|Ask||77.56 x 900|
|Day's range||77.01 - 78.25|
|52-week range||65.30 - 181.83|
|Beta (5Y monthly)||1.42|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||121.65|
CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, November 3, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2021 financial results and to provide a corporate update. The conference call may be accessed by dialing (844) 534-7313 for d
It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?
Sarepta Therapeutics (NASDAQ: SRPT), a biotech company that specializes in genetic therapies for rare diseases, dropped 14.7% this week, according to data from S&P Global Market Intelligence. To start the week, the company announced results from its three phase 3 trials for SRP-9001 to treat Duchenne muscular dystrophy (DMD), which is caused by gene mutations that disrupt the dystrophin protein that is crucial for muscle functions. The trials, which measured the response of SRP-9001 on 120 juvenile patients, said that patients improved on the North Star Ambulatory Assessment (NSAA) scale compared with untreated patients.